 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- | SAIT301 / Samsung
P1 data, Journal: Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. (Pubmed Central) - Apr 3, 2019
We successfully completed a phase I trial with MET antibody in a MET-overexpressed patient population focusing on CRC, and found that the DLTs were alkaline phosphatase elevation or hypophosphatemia. The recommended dose of SAIT301 for phase II is the dose of 3.69 mg/kg.
- | SAIT301 / Samsung
Trial completion, Enrollment change, Metastases: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types (clinicaltrials.gov) - Jan 17, 2018
P1, N=16, Completed, Sponsor: Young Suk Park
The recommended dose of SAIT301 for phase II is the dose of 3.69 mg/kg. Recruiting --> Completed | N=60 --> 16
- | SAIT301 / Samsung
Trial primary completion date, Metastases: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types (clinicaltrials.gov) - Feb 17, 2017
P1, N=60, Recruiting, Sponsor: Young Suk Park
Recruiting --> Completed | N=60 --> 16 Trial primary completion date: Dec 2016 --> Mar 2017
- SAIT301 / Samsung
Trial primary completion date, Metastases: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types (clinicaltrials.gov) - Feb 17, 2016
P1, N=60, Recruiting, Sponsor: Young Suk Park
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: May 2015 --> Dec 2016
- SAIT301 / Samsung
Enrollment open, Metastases: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types (clinicaltrials.gov) - May 26, 2015
P1, N=60, Recruiting, Sponsor: Young Suk Park
Trial primary completion date: May 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- SAIT301 / Samsung
New P1 trial, Metastases: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types (clinicaltrials.gov) - Nov 20, 2014
P1, N=60, Not yet recruiting, Sponsor: Young Suk Park